Arbekacin
Antibiotic / From Wikipedia, the free encyclopedia
Arbekacin (INN) is a semisynthetic aminoglycoside antibiotic which was derived from kanamycin. It is primarily used for the treatment of infections caused by multi-resistant bacteria including methicillin-resistant Staphylococcus aureus (MRSA).[1][2] Arbekacin was originally synthesized from dibekacin in 1973 by Hamao Umezawa and collaborators.[3] It has been registered and marketed in Japan since 1990 under the trade name Habekacin.[4] Arbekacin is no longer covered by patent and generic versions of the drug are also available under such trade names as Decontasin and Blubatosine.
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Habekacin |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Intramuscular, intravenous |
Drug class | Aminoglycoside antibiotic |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | minimal |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H44N6O10 |
Molar mass | 552.626 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Close